During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...